Opes Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Opes Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,766	Closed	-$243K	–	65
2017 Q1	$243K	Buy	+2,766	New	+$246K	0.17%	49

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Opes Advisors's BMRN Position: Q2 2017 in Review

Opes Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 2,766 shares — an estimated $243K sold.

Opes Advisors first reported a position in BMRN in Q1 2017 and held it in 1 quarter. The position peaked at $243K in Q1 2017. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

Opes Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Opes Advisors sold 2,766 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $243K.
Opes Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Opes Advisors's BioMarin Pharmaceuticals position peaked at $243K in Q1 2017.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Opes Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.